Acorda Expands Pipeline With Neuronex And New Ampyra Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Acorda Therapeutics reports strong Ampyra results in the fourth quarter and highlights the other indications it’s pursuing for the drug, as well as the consumer marketing campaign the company is about to undertake. Acorda also announced its intention to acquire privately-held Neuronex Inc. for $2 million upfront plus $500,000 in R&D funding.
You may also be interested in...
Start-Up Quarterly Statistics, Q1 2012
Biopharma start-ups raised $338.1 million – 51% less than in Q4 2011. Device companies brought in $123.7 million and diagnostics firms raised $99.3 million; Series C rounds generated more money in both the device and diagnostic sectors than any other financing type. Cancer was the most prevalent therapeutic area for biopharma alliances. During Q1, M&As across biopharma and diagnostic industries were valued at a total of $471 million.
Acorda R&D Day Explores Pipeline Opportunities
Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.
Acorda R&D Day Explores Pipeline Opportunities
Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.